1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

20 Mar 2024
Admin
News Article

Sanyou Bio & Biogeometry Partners to Make Antibody Drug Discovery Platform

Sanyou Bio and BioGeometry Team Up to Develop Innovative Antibody Drug Discovery Platform Driven by AIGC

Overview

BioGeometry and Sanyou Bio recently announced a strategic partnership agreement, signifying a significant collaboration in biotechnology.

BioGeometry

BioGeometry, a digital biology pioneer, specializes in AI-driven protein design and research and development platforms.
Sanyou Bio, on the other hand, is a prominent biotechnology enterprise focusing on innovative biologic drug research and services.

Aim for Partnership

The partnership aims to leverage both companies' expertise in generative AI technology and practical drug development experience to create a next-generation antibody drug discovery platform driven by AI.
They intend to collaborate with leading pharmaceutical companies to enhance the efficiency of new drug research and development.

Both Parties Post Agreement

Sanyou Bio will integrate BioGeometry's proprietary generative AI antibody design platform, GeoBiologics, into its operations.
Both parties will invest to create an advanced Dry-Wet antibody R&D platform by merging BioGeometry's AI algorithm dry lab platform with Sanyou Bio's wet lab capabilities.
This platform will facilitate the development of more large molecule drug pipelines and nurture innovative projects.

Sanyou Bio has established a high-throughput R&D platform for innovative antibody drugs, boasting the world's largest antibody library and cutting-edge technical resources. Their platform integrates various molecule generation technologies and automated screening processes, focusing on generating molecules with superior characteristics.

Deep Learning Models by Biogeometry

BioGeometry has developed geometric deep learning models that significantly reduce time and costs in antibody design.
Their GeoBiologics platform facilitates a closed-loop between dry and wet lab experiments, enhancing efficiency in discovering functional molecules.

Dr. Guojun Lang, CEO of Sanyou Bio, expressed confidence in BioGeometry's AI technology to transform their R&D platform, enhancing their competitiveness in new drug discovery.

CEO of Biogeometry on New Drug R&d

Dr. Jian Tang, CEO of BioGeometry, emphasized the joint creation of a cutting-edge AI-enabled antibody discovery platform with Sanyou Bio, aiming to revolutionize new drug R&D and accelerate advancements in antibody drug research.

Conclusion

In summary, the strategic partnership between BioGeometry and Sanyou Bio marks a new era of collaboration in biotechnology, with a focus on innovation and efficiency in drug discovery and development.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!